GSA Capital Partners LLP Buys Shares of 483,768 Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Key Points

• GSA Capital Partners LLP acquired 483,768 shares of Allogene Therapeutics, valued at approximately $706,000, representing 0.22% ownership after their recent purchase.
• The stock currently has a consensus rating of "Moderate Buy" with a target price of $8.44, despite varying price targets among analysts, the highest being $10.00.
• Allogene Therapeutics' stock has experienced a 12.2% decline recently, trading at $1.08, with a market capitalization of $236.23 million.

GSA Capital Partners LLP acquired a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 483,768 shares of the company's stock, valued at approximately $706,000. GSA Capital Partners LLP owned about 0.22% of Allogene Therapeutics as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of ALLO. Lynx1 Capital Management LP lifted its holdings in shares of Allogene Therapeutics by 75.3% during the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company's stock worth $23,163,000 after acquiring an additional 4,672,349 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Allogene Therapeutics by 30.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company's stock worth $7,586,000 after buying an additional 831,146 shares in the last quarter. Foresite Capital Management VI LLC bought a new position in Allogene Therapeutics during the fourth quarter valued at approximately $7,345,000. Two Sigma Advisers LP raised its position in Allogene Therapeutics by 12.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company's stock worth $5,756,000 after acquiring an additional 291,800 shares during the period. Finally, Patient Square Capital LP bought a new position in Allogene Therapeutics in the fourth quarter worth approximately $3,174,000. Hedge funds and other institutional investors own 83.63% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on ALLO. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Allogene Therapeutics in a research note on Monday. Piper Sandler dropped their price objective on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Robert W. Baird reduced their target price on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Truist Financial lowered their price objective on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Oppenheimer cut their target price on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.44.

Allogene Therapeutics Stock Performance

ALLO traded down $0.06 during midday trading on Wednesday, reaching $1.07. 4,440,784 shares of the company were exchanged, compared to its average volume of 4,371,393. The company's fifty day moving average price is $1.28 and its 200 day moving average price is $1.50. The company has a market cap of $232.95 million, a price-to-earnings ratio of -0.87 and a beta of 0.35. Allogene Therapeutics, Inc. has a one year low of $0.86 and a one year high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). As a group, sell-side analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).